Efficacy of transdiagnostic approach versus cognitive behavioral in paranoid

Phase 2

• Conditions: Delusional disorders; Subclinical paranoia.

• Registration Number: IRCT20150315021482N4
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 July 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 30

Inclusion Criteria

Subclinical paranoia scoring>1 based on the SCL-90 questionnaire and scoring>40 in the paranoia scale
Living in Mashhad city at the time of group therapy

Exclusion Criteria

Substance dependence
A case note DSM-V diagnosis of schizophrenia and any psychotic disorder
Already being in receipt of psychological therapy
Organic impairments

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Paranoid ideation. Timepoint: pre-intervention, post intervention, 3 months after intervention. Method of measurement: In screening Based on score >1 in PAR; sub-scale in SCL90-R and score>40 in Paranoia scale. Totally, in pre-intervention, post- intervention and follow-up, Paranoia scale is used for measure paranoia.;General performance. Timepoint: pre-intervention, post intervention, 3 months after intervention. Method of measurement: Work and Social Adjustment Scale.

Secondary Outcome Measures

Name	Time	Method
Depression. Timepoint: Pre and post intervention and 3 months follow up. Method of measurement: Beck depression inventory.;Anxiety. Timepoint: Pre and post intervention and 3 months follow up. Method of measurement: Beck anxiety inventory.